Quanterix Announces Commercialization of p-Tau 217 Test Kit

QTRX 09.30.2024

Full Press ReleaseSEC FilingsOur QTRX Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - Quanterix to Present at 43rd Annual J.P. Morgan Healthcare Conference
  • 01.14.2025 - Quanterix Provides Update on Financial Performance
  • 01.10.2025 - Quanterix Corporation to Acquire Akoya Biosciences

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 425 Prospectuses and communications, business combinations
  • 01.16.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
PDF Version

Quanterixexpands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly

BILLERICA, Mass.--(BUSINESS WIRE)--Sep. 30, 2024--Quanterix Corporation(NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced it is making its Simoa® p-Tau 217 Planar Kit commercially available as part of the next phase of Alzheimer’s Disease (AD) test development. The kit uses p-Tau 217 antibody technology licensed from Eli Lilly and Company and Quanterix’s SP-X platform.

InMarch 2022,Quanterixfirstannouncedits entry into license and collaboration agreements with Lilly, which specified the initial development of a test for theEli Lilly Clinical Diagnostics Laboratory(ELCDL), a wholly owned subsidiary of Lilly. Now, with the Simoa® p-Tau 217 Planar Kit,Quanterixwill expand access to this technology by selling customers research use only (RUO) instrumentation and consumables to develop p-Tau 217 blood tests and services using p-Tau 217 antibody technology licensed from Lilly. The Simoa® p-Tau 217 Planar Kit will be available immediately.

“We are excited to expand access to high-performing, non-invasive p-Tau 217 testing,” saidMasoud Toloue, CEO ofQuanterix. “Quanterix continues to focus on building a global infrastructure that supports blood-based testing for Alzheimer’s Disease. With the broader availability of the Lilly antibody technology and Simoa’s sensitivity, we are prepared to lead Alzheimer's Disease testing for groundbreaking new research and therapies, ultimately supporting the advancement of care and outcomes for patients.”

“Lilly is committed to enabling and supporting the development of high-quality diagnostics for Alzheimer’s Disease,” saidAnthony Sireci, M.D., Msc., Head of theDiagnostics Development & Commercializationfor Lilly. “We’re excited about collaborating withQuanterixto advance blood-based biomarkers and licensing Lilly technology to achieve this aim.”

AboutQuanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease.Quanterixhas been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about theBillerica, Massachusetts-based company athttps://www.quanterix.comor follow us on Twitter and LinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20240930378392/en/

Media Contact:PAN CommunicationsMaya Nimnicht(510) 334-6273quanterix@pancomm.com

Investor Relations Contact:Francis Pruell,Quanterix(508) 789-1725ir@quanterix.com

Source:Quanterix Corporation

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com